Login to Your Account

VeroScience's Cycloset Gets FDA Nod in Type II Diabetes

By Jennifer Boggs

Thursday, May 7, 2009
VeroScience LLC emerged from stealth mode Wednesday to report that its lead product Cycloset gained FDA approval, making it the first dopamine agonist for treating Type II diabetes and also the first diabetes drug to get the agency's nod under the new cardiovascular safety guidelines adopted for diabetes drugs last year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription